Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTEDEXAMAMA: Dexamethasone Omission in Breast Cancer
NCT04350229Completed
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Start
- Mar 2020
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of dexamethasone in breast cancer (2 arms), sponsored by Instituto do Câncer do Estado de São Paulo. Primary endpoint: The incidence and change of endocrine dysfunction at 36 months. Started Mar 2020; status: completed.
02
Drugs
dexamethasone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04350229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04350229.